European Commission Slaps AstraZeneca With €60M Fine For Patent Abuse

Law360, New York (June 15, 2005, 12:00 AM EDT) -- European antitrust authorities have fined Anglo-Swedish drug maker AstraZeneca PLC €60 million for abusing patent systems to thwart generic competition for the blockbuster ulcer drug Losec.

According to a finding by the European Commission, AstraZeneca violated competition rules by blocking or delaying market access for generic versions of Losec and preventing parallel imports of Losec from 1993 to 2000.

The Commission said AstraZeneca had made “misleading” applications to patent offices that gave the firm longer patent protection and exclusive rights.

Moreover, it found that AstraZeneca had...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.